Cancer Metabolism

Genetic alterations and epigenetic modifications of cancer cells result in cellular metabolic pathways that are different in comparison to normal cells. Due to the inherent genetic instability of cancer cells, tumors are heterogeneous with a myriad microenvironments and multiple altered metabolic pathways, which could provide useful cancer therapeutic targets.

Cancer Metabolism Products Targets

Products for Cancer Metabolism - Page 4

Cat.No. Product Name Information/Activity
BCC7994 CHC 28166-41-8
BCC2021 UK-5099 UK-5099 (PF-1005023) is a potent inhibitor of the mitochondrial pyruvate carrier (MPC). UK-5099 (PF-1005023) inhibits pyruvate-dependent O2 consumption with an IC50 of 50 nM.
BCC5613 SCH 51344 Potent MTH1 inhibitor
BCC6432 CARIPORIDE Cariporide (HOE-642) is a selective Na+/H+ exchange inhibitor.
BCC7672 EIPA EIPA (L593754) is a TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also inhibits Na+/H+-exchanger (NHE) and macropinocytosis.
BCC7461 Zoniporide dihydrochloride 241799-10-0
BCC7986 Methylmalonate Methylmalonic acid (Methylmalonate) is an indicator of Vitamin B-12 deficiency in cancer.
BCC6303 3-Nitropropionic acid 3-Nitropropanoic acid (β-Nitropropionic acid) is an irreversible inhibitor of succinate dehydrogenase. 3-Nitropropanoic acid exhibits potent antimycobacterial activity with a MIC value of 3.3 μM.
BCN5412 Rotenone Rotenone is an mitochondrial electron transport chain complex I inhibitor. Rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production.
BCC5658 CCCP CCCP is an oxidative phosphorylation uncoupler. CCCP induces activation of PINK1 leading to Parkin Ser65 phosphorylation.